Menzies Health Institute Queensland, School of Medical Science, Griffith University, Gold Coast Campus, Gold Coast, QLD 4222, Australia.
Department of Regional Science Operations, La Trobe Rural Health School, Albury-Wodonga, Flora Hill, VIC 3690, Australia.
Mar Drugs. 2022 Mar 13;20(3):208. doi: 10.3390/md20030208.
This review highlights the underexplored potential and promises of marine bioactive peptides (MBPs) with unique structural, physicochemical, and biological activities to fight against the current and future human pathologies. A particular focus is given to the marine environment as a significant source to obtain or extract high-value MBPs from touched/untouched sources. For instance, marine microorganisms, including microalgae, bacteria, fungi, and marine polysaccharides, are considered prolific sources of amino acids at large, and peptides/polypeptides in particular, with fundamental structural sequence and functional entities of a carboxyl group, amine, hydrogen, and a variety of R groups. Thus, MBPs with tunable features, both structural and functional entities, along with bioactive traits of clinical and therapeutic value, are of ultimate interest to reinforce biomedical settings in the 21st century. On the other front, as the largest biome globally, the marine biome is the so-called "epitome of untouched or underexploited natural resources" and a considerable source with significant potentialities. Therefore, considering their biological and biomedical importance, researchers around the globe are redirecting and/or regaining their interests in valorizing the marine biome-based MBPs. This review focuses on the widespread bioactivities of MBPs, FDA-approved MBPs in the market, sustainable development goals (SDGs), and legislation to valorize marine biome to underlying the impact role of bioactive elements with the related pathways. Finally, a detailed overview of current challenges, conclusions, and future perspectives is also given to satisfy the stimulating demands of the pharmaceutical sector of the modern world.
这篇综述强调了海洋生物活性肽(MBPs)的潜力和承诺,这些肽具有独特的结构、物理化学和生物学活性,可以对抗当前和未来的人类疾病。特别关注海洋环境作为一个重要的来源,从受影响/未受影响的来源中获得或提取高价值的 MBPs。例如,海洋微生物,包括微藻、细菌、真菌和海洋多糖,被认为是氨基酸的丰富来源,特别是肽/多肽,具有羧基、胺基、氢和各种 R 基团的基本结构序列和功能实体。因此,具有可调节结构和功能实体以及具有临床和治疗价值的生物活性特征的 MBPs,是 21 世纪强化生物医学领域的最终关注点。另一方面,作为全球最大的生物群落,海洋生物群落是所谓的“未受影响或未充分开发的自然资源的缩影”,是一个具有巨大潜力的重要来源。因此,考虑到它们的生物学和生物医学重要性,全球的研究人员正在重新关注或重新获得利用基于海洋生物群落的 MBPs 的兴趣。本综述重点介绍了 MBPs 的广泛生物活性、市场上获得 FDA 批准的 MBPs、可持续发展目标(SDGs)和立法,以挖掘海洋生物群落中的生物活性元素及其相关途径的影响作用。最后,还详细概述了当前的挑战、结论和未来展望,以满足现代世界制药行业的刺激需求。